Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020

Rhea-AI Summary

Caladrius Biosciences (Nasdaq: CLBS) announced its participation in the American Heart Association's (AHA) Scientific Sessions from November 13-17, 2020, with a presentation focused on COVID-19. The session will feature an abstract titled Autologous CD34+ Cells (CLBS119) for Repair of Covid-19 Induced Microvascular Lung Damage: Rationale and Study Design, presented by Chief Medical Officer Douglas W. Losordo. This highlights the company's commitment to cellular therapies that reverse diseases and address the pulmonary damage caused by the virus.

BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart Association’s (“AHA”) Scientific Sessions, being held virtually November 13-17, 2020.

AHA Virtual Scientific Sessions 2020

Session Type:	Abstract Poster Session
Session Title:	COVID-19: Mechanism and Observations
Abstract Title:	Autologous CD34+ Cells (CLBS119) for Repair of Covid-19 Induced Microvascular Lung Damage: Rationale and Study Design
Presenter:	Douglas W. Losordo, M.D., FACC, FAHA, Chief Medical Officer of Caladrius Biosciences

Note: This session is OnDemand and will be available via AHA Scientific Session’s virtual platform on November 13, 2020 at 9:00 a.m. (CST) until November 17, 2020 at 8:30 p.m. (CST).

Evidence from research by others indicates that severe cases of COVID-19 are accompanied by damage to the pulmonary endothelium.^1,2 These data indicate SARS-CoV2 is particularly avid for the lung microvascular endothelium, destroying microvascular integrity. Destruction of microvascular integrity appears to be one of the mechanisms by which COVID-19 causes severe loss of lung function that appears to persist after acute recovery. CD34+ cells have pre-programmed tissue repair effects mediated by pro-angiogenic functions.³ Restoration of the microvasculature by pro-angiogenic therapies has been associated with regeneration of damaged organ function.^4-9

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: HONEDRA^® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of a recently completed positive Phase 2a clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients. For more information on the company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com

Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com

1. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, and Moch H, Endothelial cell infection and endotheliitis in COVID-19. Lancet, 2020. 395(10234): p. 1417-1418.
2. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, and Jonigk D, Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med, 2020.
3. Berenson RJ, Andrews RG, Bensinger WI, Kalamasz D, Knitter G, Buckner CD, and Bernstein ID, Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest, 1988. 81(3): p. 951-955.
4. Kawamoto A, Katayama M, Handa N, Kinoshita M, Baba R, Takano H, Kihara Y, Morioka S, Fukushima M, and Asahara T, Safety and efficacy is sustained up to one year after transplantation of autologous CD34+ cells in no-option patients with chronic critical limb ischemia. Circulation, 2006. 114(18 Supplement): p. II-264 Abstract.
5. Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, and Henry TD, Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation, 2007. 115(25): p. 3165-3172.
6. Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M, Sadamoto K, Yokoyama A, Yamanaka T, Onodera R, Kuroda A, Baba R, Kaneko Y, Tsukie T, Kurimoto Y, Okada Y, Kihara Y, Morioka S, Fukushima M, and Asahara T, Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells, 2009. 27(11): p. 2857-2864.
7. Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA, and Investigators AC, Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res, 2011. 109(4): p. 428-436.
8. Losordo DW, Kibbe MR, Mendelsohn F, Marston W, Driver VR, Sharafuddin M, Teodorescu V, Wiechmann BN, Thompson C, Kraiss L, Carman T, Dohad S, Huang P, Junge CE, Story K, Weistroffer T, Thorne TM, Millay M, Runyon JP, and Schainfeld R, A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv, 2012. 5(6): p. 821-830.
9. Ohtake T, Mochida Y, Ishioka K, Oka M, Maesato K, Moriya H, Hidaka S, Higashide S, Ioji T, Fujita Y, Kawamoto A, Fukushima M, and Kobayashi S, Autologous Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood CD34 Positive Cell Transplantation for Hemodialysis Patients with Critical Limb Ischemia: A Prospective Phase II Clinical Trial. Stem Cells Transl Med, 2018. 7(11): p. 774-782.

FAQ

What is Caladrius Biosciences presenting at the AHA Scientific Sessions 2020?

Caladrius Biosciences is presenting an abstract on the use of Autologous CD34+ Cells (CLBS119) to repair COVID-19 induced microvascular lung damage.

When are the AHA Scientific Sessions 2020?

The AHA Scientific Sessions 2020 are being held virtually from November 13-17, 2020.

Who is presenting for Caladrius at the AHA event?

Dr. Douglas W. Losordo, Chief Medical Officer of Caladrius Biosciences, is the presenter.

What is the focus of Caladrius' presentation at the AHA conference?

The focus is on the mechanisms of COVID-19 and how Autologous CD34+ Cells (CLBS119) can repair lung damage.

Where can I access the AHA Scientific Sessions 2020 presentation?

The session is available on the AHA Scientific Session’s virtual platform from November 13, 2020, at 9:00 a.m. CST until November 17, 2020, at 8:30 p.m. CST.